9 Facts About Inositol and Why It Helps Women in Perimenopause With Insulin Resistance
When the weight started creeping on despite nothing changing in diet or exercise, and the afternoon energy crashes became a daily event, it felt like the body had switched to different rules overnight. Nobody mentioned insulin resistance as part of perimenopause — it took falling down a research rabbit hole to find inositol, and even longer to understand why it made biological sense. If that pattern sounds familiar, this one is for you.
Learn more about Rose →Inositol Is Not a Single Compound — It's a Family of Nine
Inositol refers to a group of nine stereoisomers, but two dominate the research relevant to women's hormonal health: myo-inositol (MI) and D-chiro-inositol (DCI). Both are naturally present in the body and in food, with myo-inositol being the most abundant form in human tissues. Understanding which form is being discussed matters enormously, because they act on different parts of the insulin signalling pathway and have different optimal doses.
It Acts as a Secondary Messenger for Insulin — Which Is Why It Targets the Root Problem
Inositol phosphoglycans derived from myo-inositol and D-chiro-inositol function as secondary messengers in the insulin signalling cascade — essentially, they help carry insulin's instructions into the cell after the hormone has docked at its receptor. When this messenger system is deficient or disrupted, cells become less responsive to insulin even when insulin levels are normal or elevated, which is the mechanistic definition of insulin resistance. Supplementing inositol addresses this intracellular signalling deficit rather than simply stimulating more insulin production.
Oestrogen Regulates Inositol Metabolism — So Perimenopause Disrupts It Directly
Oestrogen upregulates the enzyme epimerase, which converts myo-inositol into D-chiro-inositol in tissues that need it for insulin signalling, including the ovaries, liver, and muscle. As oestrogen declines in perimenopause, epimerase activity drops, meaning D-chiro-inositol availability falls even if dietary inositol intake remains the same. This creates a functionally inositol-deficient state in key metabolic tissues, which helps explain why insulin resistance can emerge or worsen during the menopause transition independently of diet or activity changes.
The PCOS Evidence Is the Strongest Foundation We Have
Multiple randomised controlled trials and meta-analyses in women with PCOS have shown that myo-inositol supplementation — particularly at a 40:1 ratio of MI to DCI — improves insulin sensitivity, lowers fasting insulin, reduces androgen levels, and restores ovulatory function. A 2019 Cochrane-adjacent meta-analysis of 13 RCTs found significant reductions in HOMA-IR (a standard insulin resistance marker) compared to placebo. Because PCOS is fundamentally a condition of insulin-driven hormonal dysregulation, and perimenopause produces a similar metabolic environment through oestrogen withdrawal, the mechanistic overlap is considered clinically meaningful.
Direct Perimenopause and Postmenopause Trials Are Smaller but Encouraging
Research specifically in perimenopausal and postmenopausal women is more limited, but early RCTs have shown that myo-inositol supplementation improves fasting glucose, fasting insulin, and HOMA-IR scores in postmenopausal women with metabolic syndrome. A 2012 Italian RCT published in Menopause found that 2g of myo-inositol twice daily significantly reduced insulin resistance markers and blood pressure compared to placebo over six months. These findings are promising rather than definitive, and larger trials are still needed — but the direction of effect is consistent with the mechanistic rationale.
It Appears to Reduce Visceral Fat Accumulation — the Type That Drives Metabolic Risk
Visceral adipose tissue — the metabolically active fat stored around abdominal organs — increases significantly during the menopause transition and is strongly linked to insulin resistance, cardiovascular risk, and inflammation. Studies in both PCOS populations and postmenopausal women suggest inositol supplementation reduces waist circumference and visceral fat markers beyond what would be expected from insulin improvement alone. The proposed mechanism involves inositol's role in adipocyte differentiation and lipid metabolism signalling, though this pathway is less thoroughly characterised than its insulin-related effects.
Myo-Inositol Has a Genuine Effect on Anxiety — Via GABA, Not Just Blood Sugar
Inositol is a precursor to phosphatidylinositol, a phospholipid involved in serotonin and GABA receptor function in the brain. Several double-blind RCTs — including one published in the American Journal of Psychiatry — found that high-dose myo-inositol (12–18g/day) outperformed placebo for panic disorder and matched fluvoxamine for obsessive-compulsive symptoms with fewer side effects. Perimenopausal anxiety has multiple drivers including GABA dysregulation from progesterone withdrawal, and inositol's GABAergic support makes it mechanistically relevant beyond its metabolic effects.
It May Improve Sleep Quality Indirectly Through Insulin and Cortisol Stabilisation
Blood sugar instability — particularly nocturnal hypoglycaemia following insulin resistance-driven dysregulation — is an underappreciated driver of night wakings and poor sleep architecture in perimenopause. By improving insulin sensitivity and reducing fasting insulin, inositol may help stabilise overnight glucose, which dampens the cortisol spikes that interrupt sleep in the early hours. There are no large RCTs specifically examining inositol and sleep in perimenopausal women, so this connection is mechanistically plausible and supported by indirect evidence rather than direct trial data.
The Typical Effective Dose Is Well-Tolerated — With One Important Ratio Caveat
Most clinical trials use 2–4g of myo-inositol daily, often split into two doses, and the safety profile across hundreds of trials is consistently good — mild gastrointestinal symptoms at higher doses being the main reported issue. The 40:1 ratio of myo-inositol to D-chiro-inositol has emerged as important because excessive DCI supplementation can paradoxically worsen ovarian function and oocyte quality in some contexts, likely by depleting the MI that ovarian follicles specifically require. Women considering inositol for perimenopausal metabolic symptoms should be aware of this ratio when evaluating products, and as always, any supplementation is worth discussing with a clinician — particularly for those on diabetes or blood pressure medications where additive effects are possible.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.